October 2023 - ProRelix Research

Monthly Archives: October 2023

Oct

eCOA in Clinical Trials: A Game-Changer for Data Collection

Discover how eCOA in clinical trials transforms data collection and uncover the game-changing benefits of electronic data capture in clinical research.

Introduction: What is eCOA in Clinical Trials?

eCOA in clinical trials are a type of clinical research in the field of healthcare and medicine. eCOA refers to the use of electronic methods and technologies to collect patient-reported outcomes and other clinical data in a clinical trial setting. These electronic methods can include the use of smartphones, tablets, wearable devices, web-based platforms, or other digital tools to record and transmit information about a patient’s symptoms, experiences, and overall health status.

The primary goal of eCOA clinical trials is to improve the accuracy and efficiency of data collection during clinical research. By using electronic tools, researchers can reduce the potential for errors associated with manual data entry and streamline the data collection process, making it more convenient for both patients and investigators. eCOA methods are often used to assess patient-reported outcomes such as quality of life, symptom severity, and treatment-related side effects.

Significance of eCOA in Clinical Trials

eCOA, or Electronic Clinical Outcome Assessment, has emerged as a pivotal tool in modern clinical trials. eCOA in Clinical Trials offers numerous advantages, enhancing data accuracy and patient engagement, making it a fundamental aspect of contemporary research methodologies. By enabling patients to input their health-related information directly into electronic devices, eCOA minimizes transcription errors and streamlines data collection, ultimately improving the quality of trial outcomes. Furthermore, eCOA’s ability to facilitate remote data capture has become especially vital in the context of global health crises, ensuring trial continuity and participant safety. As we navigate the evolving landscape of clinical research, eCOA Clinical Trials remains at the forefront, revolutionizing the way we gather and utilize critical data.

The Advantages of eCOA in Clinical Trials over Traditional Paper-Based Data Collection Methods

The advantages of Electronic Clinical Outcome Assessment (eCOA) over traditional paper-based data collection methods presented in bullet points:

Figure: The Advantages of eCOA in Clinical Trials over Traditional Paper-Based Data Collection Methods

Data Accuracy and Integrity

Reduced risk of transcription errors and data entry mistakes.
Real-time data validation and automated skip patterns enhance data quality.

Time and Cost Efficiency

Eliminates the need for printing, shipping, and storing paper forms.
Faster data collection, review, and analysis, leading to shorter study timelines.

Patient Engagement

User-friendly interfaces improve patient compliance and satisfaction.
The ability to collect data remotely encourages broader patient participation.

Real-Time Monitoring

Researchers can access data instantly, enabling prompt response to issues.
Early identification of adverse events or protocol deviations.

Data Security and Compliance

Enhanced data encryption and audit trails protect sensitive patient information.
Adherence to regulatory standards (e.g., 21 CFR Part 11) is facilitated.

Eco-Friendly

Reduces paper waste, contributing to a greener and more sustainable approach.
Aligns with environmental responsibility goals.

Integration with Other Systems

Easily integrates with Electronic Data Capture (EDC) and other clinical trial systems.
Streamlines data flow and enhances the overall efficiency of clinical trials.

Remote Data Collection

Allows for remote patient monitoring and data collection, reducing the need for physical site visits.
Particularly valuable during global health crises (e.g., pandemics) to maintain data collection continuity.

Data Accessibility and Sharing

Facilitates secure data sharing among stakeholders, including sponsors, CROs, and regulatory authorities.
Enhances transparency in the research process.

Reduced Administrative Burden

Minimizes the need for manual data handling, reducing administrative workload.
Automates data collection and management tasks.

Customization and Adaptability

Easily configurable to specific study requirements.
Can accommodate a wide range of study types and data formats.

Improved Data Traceability

Easy tracking of data changes and user interactions, aiding in the audit trail.
Enhances the ability to reconstruct data history if needed.

Enhanced Patient-Reported Outcomes (ePROs)

Supports the collection of patient-reported outcomes more efficiently and accurately.
Provides a patient-centric approach to data collection.

Quality of Life Assessments

Allows for real-time assessment of quality of life measures, particularly important in long-term studies or chronic disease research.

Geographic Reach

Overcomes geographical barriers, enabling participation of patients from diverse locations.
Facilitates multi-site and global clinical trials.

These advantages demonstrate how eCOA methods offer a significant improvement over traditional paper-based data collection in clinical research, leading to more efficient, reliable, and patient-centric outcomes.

How eCOA in Clinical Trials Enhances Patient Engagement and Retention?

Electronic Clinical Outcome Assessments (eCOA) have revolutionized the way clinical trials are conducted, offering a range of benefits, including the enhancement of patient engagement and retention. Patient engagement and retention are critical factors in the success of clinical trials, as they directly impact the quality and reliability of the data collected. Here’s how eCOA achieves this:

Convenience and Accessibility

eCOA platforms provide patients with the flexibility to complete assessments from the comfort of their own homes, reducing the need for in-person visits. This convenience makes it easier for patients to participate in the trial, especially those who may have mobility issues or live far from trial sites. As a result, patients are more likely to stay engaged throughout the trial’s duration.

Real-time Communication

eCOA systems enable real-time communication between patients and researchers. This means that patients can quickly report any issues or concerns, fostering a sense of being closely monitored and cared for. This transparency can improve patient satisfaction and trust in the clinical trial process.

User-Friendly Interfaces

eCOA platforms often come with user-friendly interfaces that are easy for patients to navigate. This reduces the burden on patients, making it less likely for them to become overwhelmed or frustrated with the assessment process. A positive user experience encourages patients to stay engaged in the trial.

Automated Reminders

eCOA systems can send automated reminders to patients, prompting them to complete assessments on time. This minimizes the risk of missed assessments and improves data reliability. Patients are more likely to remain engaged when they receive gentle reminders about their responsibilities in the trial.

Customization

eCOA platforms allow for the customization of assessments to better match a patient’s condition and individual needs. This personalized approach can make patients feel more valued, enhancing their commitment to the trial.

Data Visualization

Patients can often access their own assessment data through eCOA platforms, allowing them to track their progress. This visibility into their health data empowers patients and keeps them engaged in the study.

Reduced Burden

Paper-based assessments can be burdensome for patients, leading to fatigue and dropout. eCOA streamlines data collection and reduces the need for excessive paperwork. Patients are more likely to remain engaged when the process is simplified.

Safety and Compliance Checks

eCOA platforms can include built-in safety checks and validation rules, which ensure that patients provide accurate and complete data. This enhances data quality and compliance while giving patients a sense that their safety is a priority.

Data Security and Privacy in eCOA Clinical Trials

eCOA systems are designed to maintain the privacy and security of patient data. This assurance can make patients more comfortable with sharing their information, knowing that it will be handled with the utmost care.

Ensuring data security and privacy in electronic Clinical Outcome Assessments (eCOA) clinical trials is critical to safeguard patient information, maintain data integrity, and meet regulatory requirements. To achieve this, adherence to relevant data protection regulations, such as GDPR in Europe and HIPAA in the United States, is paramount. Robust encryption measures for data in transit and at rest should be in place to protect data from unauthorized access.

Strong user authentication, role-based access control, and audit trails help manage and monitor data access effectively. Data minimization practices, secure data storage, and encrypted data transmission are essential for protecting patient information. Furthermore, eCOA device security, oversight of third-party vendors, and informed consent processes are crucial to maintaining data security and patient privacy.

Well-defined data retention and disposal policies, along with a comprehensive data breach response plan, further enhance data protection. Regular training, awareness initiatives, and continuous monitoring ensure that data security remains a top priority throughout the eCOA clinical trial process.

Data Integrity and Compliance in eCOA Clinical Trials

eCOA in clinical trials plays a critical role in ensuring data integrity and compliance in clinical trials. In an era where clinical research is becoming increasingly complex and data-driven, eCOA solutions have emerged as a powerful tool to enhance the quality of data collection, reduce errors, and streamline the regulatory compliance process.

Data Accuracy and Consistency

One of the primary benefits of eCOA is its ability to ensure the accuracy and consistency of data collected during clinical trials. By replacing paper-based assessments with electronic data capture methods, eCOA systems eliminate the risk of transcription errors, missing data, and illegible handwriting that can plague traditional data collection processes. This not only improves the quality of data but also minimizes the need for data cleaning, reducing the time and resources required for this tedious task.

Real-time Data Monitoring

eCOA systems enable real-time data monitoring, allowing sponsors and investigators to review and assess data as it is collected. This capability enhances the ability to detect discrepancies or irregularities promptly, facilitating timely corrective actions. In case of any issues or non-compliance with the trial protocol, immediate intervention is possible, preventing the accumulation of inaccuracies that could compromise the trial’s integrity.

Protocol Adherence

Clinical trial protocols are carefully designed to ensure patient safety, study integrity, and compliance with regulatory requirements. eCOA solutions can include built-in checks and validations to ensure that data collected aligns with the defined protocol. For instance, eCOA systems can flag entries that fall outside predefined ranges, require mandatory fields to be completed, or provide automated skip patterns based on participant responses. This promotes protocol adherence and minimizes deviations that could jeopardize data integrity.

Audit Trails and Data Security

Data integrity and compliance are closely related to data security. eCOA systems provide robust security measures to protect sensitive patient information and research data. Furthermore, these systems often maintain detailed audit trails that record every interaction with the data, including who accessed it, when, and what changes were made. This audit trail is invaluable for regulatory compliance and data integrity, as it allows complete traceability and accountability for all data-related actions.

Regulatory Compliance

eCOA solutions are designed with the latest regulatory guidelines and standards in mind, ensuring that clinical trials are conducted in accordance with Good Clinical Practice (GCP) and other relevant regulations. Data captured through eCOA is more likely to meet regulatory requirements due to its reduced risk of errors and the ability to implement necessary compliance checks. This minimizes the risk of non-compliance, which can result in regulatory sanctions or invalidated trial results.

Patient Engagement and Compliance in eCOA Clinical Trials

The user-friendly interfaces and remote data collection options of eCOA systems make it easier for participants to submit their data accurately and consistently. Patient compliance is crucial in maintaining data integrity, and eCOA can help by simplifying the data collection process for study participants.

The use of electronic methods for data collection in these trials, such as smartphones and web-based applications, not only simplifies the process for patients but also improves data accuracy through validation checks and real-time monitoring. eCOA systems can be designed with a patient-centric approach, offering flexible assessment times and automated reminders, reducing the burden on participants.

Remote monitoring and data collection enable decentralized trials and geographic diversity in recruitment. Privacy and security, compliance with data protection regulations, education, and training are crucial factors to ensure patient trust and effective use of eCOA. Additionally, the feedback loop facilitated by eCOA systems allows patients to report adverse events and concerns directly, contributing to quicker responses and improved patient safety. In eCOA clinical trials benefit significantly from enhanced patient engagement and compliance, ultimately leading to higher-quality data and study success.

Considerations for Implementing eCOA in Your Clinical Trials

Implementing eCOA in clinical trials can streamline data collection and enhance the overall efficiency of your research. Here are seven key considerations for successfully implementing eCOA in your clinical trials:

Regulatory Compliance

Ensure that your eCOA system complies with the regulatory requirements of the regions where your clinical trials are conducted. Familiarize yourself with guidelines such as 21 CFR Part 11 in the United States and similar regulations in other countries.

Device Compatibility

Consider the various devices that participants may use to enter data, such as smartphones, tablets, or web browsers. Ensure that your eCOA system is compatible with these devices, taking into account factors like screen size and operating systems.

Patient Engagement

Engage with patients early in the trial planning process to ensure their comfort and willingness to use the eCOA system. Provide training and support to help participants become familiar with the technology.

Data Security

Prioritize the security of patient data. Implement robust data encryption, user authentication, and access controls to safeguard sensitive information. Regularly update security protocols to stay ahead of emerging threats.

Data Validation and Quality Assurance

Establish rigorous data validation and quality assurance processes. These should include edit checks, audit trails, and monitoring for missing or inconsistent data. Ensuring data integrity is crucial for the credibility of your trial results.

Integration with Other Systems

Consider how the eCOA system will integrate with other trial-related software, such as electronic data capture (EDC) systems and ePRO (electronic patient-reported outcomes) databases. Seamless integration can reduce data transfer errors and streamline trial management.

By addressing these considerations, you can maximize the benefits of eCOA in your clinical trials, such as improved data accuracy, increased patient engagement, and enhanced trial efficiency. However, it’s essential to adapt your approach to the specific needs and circumstances of your trial and continuously monitor and refine your eCOA implementation throughout the study.

eCOA Clinical Trials Future Trends and Innovations

eCOA (Electronic Clinical Outcome Assessment) is rapidly shaping the future of clinical trials. This innovative technology is revolutionizing data collection by streamlining the process, enhancing patient engagement, and improving data quality and integrity. With the increased adoption of eCOA in clinical trials, we can expect a shift towards more patient-centric approaches, real-time data monitoring, and a reduction in human errors. These advancements hold the potential to significantly enhance the overall success and efficiency of clinical trials, ultimately benefiting both patients and researchers.

Future trends and innovations in the field of eCOA in clinical trials:

eCOA Clinical Trials Future Trends and Innovations

Figure: eCOA Clinical Trials Future Trends and Innovations

Digital Biomarkers Integration

The integration of digital biomarkers in eCOA (Electronic Clinical Outcome Assessments) is expected to become a significant trend. These biomarkers, collected from wearable devices and mobile apps, can provide real-time, objective data on patients’ health and well-being, enhancing the quality and accuracy of clinical trial assessments.

Patient-Centric eCOA Design

Future eCOA solutions will prioritize patient-centric design, making it easier for patients to participate in clinical trials. This includes user-friendly interfaces, multilingual options, and customizable assessments to ensure patients’ diverse needs are met.

Real-World Evidence (RWE) Integration

To streamline drug development, eCOA systems will increasingly incorporate real-world evidence from electronic health records and other sources. This data can provide a more comprehensive view of a drug’s effectiveness and safety profile in real-world settings.

AI and Machine Learning for Data Analysis

Artificial intelligence and machine learning algorithms will play a vital role in eCOA data analysis. These technologies can identify subtle trends, predict patient outcomes, and enhance the efficiency of clinical trials by automating data quality control and anomaly detection.

Remote Monitoring and Telehealth

The COVID-19 pandemic accelerated the adoption of remote monitoring and telehealth solutions in clinical trials. eCOA systems will continue to support virtual patient visits, enabling real-time data collection, reducing the need for in-person visits, and increasing patient retention rates.

Blockchain for Data Security

Given the sensitivity of clinical trial data, blockchain technology is expected to be increasingly employed to ensure the security, integrity, and traceability of eCOA data. This will enhance data privacy, reduce fraud, and improve transparency in clinical trial operations.

Regulatory Advances

As eCOA systems become more sophisticated and widely adopted, regulatory bodies like the FDA will likely provide clearer guidance and regulations to ensure data quality, patient privacy, and the validity of eCOA in clinical trials. Staying informed and compliant with these evolving regulations will be crucial for sponsors and Clinical Research Organizations.

These trends and innovations in the field of eCOA for clinical trials are expected to reshape the way trials are conducted, making them more patient-centric, data-driven, and efficient. It’s crucial for stakeholders in the pharmaceutical and clinical research industries to stay updated with these developments to remain competitive and ensure the successful execution of clinical trials.

Embrace the Power of eCOA to Transform Your Clinical Trial Data Collection Process

Embrace the Power of eCOA to Transform Your Clinical Trial Data Collection Process. In today’s rapidly evolving landscape, hybrid clinical trials have become a pivotal component in drug development. Leveraging Electronic Clinical Outcome Assessments (eCOA) can significantly enhance the efficiency and accuracy of data collection in these trials. By incorporating eCOA solutions, you can seamlessly capture patient-reported outcomes and clinical data, ensuring a streamlined and patient-centric approach that optimizes the success of your hybrid clinical trials. The impact of eCOA on data quality and integrity is profound, offering real-time, accurate, and patient-centric data collection that enhances the reliability of clinical trial results. By replacing traditional paper-based methods with digital, patient-friendly platforms, eCOA streamlines data collection, reduces errors, and ultimately contributes to more efficient and successful clinical trials.

Conclusion

eCOA (electronic Clinical Outcome Assessment) has undeniably emerged as a game-changer in the realm of clinical trials, revolutionizing the way data is collected and transforming the entire research landscape. With its numerous advantages, including increased data accuracy, patient engagement, and cost-efficiency, eCOA has proven to be an indispensable tool for researchers and pharmaceutical companies alike. As the clinical trials industry continues to evolve, embracing eCOA is not just a choice but a necessity to enhance the quality and efficiency of data collection, ultimately expediting the development of innovative therapies and improving patient outcomes. In a world driven by technology and innovation, eCOA in clinical trials has unquestionably earned its place as a pivotal keyword in the pursuit of cutting-edge research and healthcare advancements.

Oct

Digital Health Technologies in Pharmacovigilance

Pharmacovigilance is defined as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects and other drug-related problems. It is an important component of the post-marketing surveillance program of medicinal products and medical devices as it helps monitor adverse effects (AE), adverse drug reactions (ADR), and any other safety concerns that were not captured during clinical trials. Safety data from pharmacovigilance activities is critical as it gives information about the benefits/side effects of the drug in a diverse patient population and helps detect any new and previously unreported risks. Although several pharmacovigilance systems are in place and most companies employ pharmacovigilance activities, it is often possible to miss some important safety information and underreporting is common. The FDA pharmacovigilance systems voluntary reporting systems such as MedWatch for consumers and healthcare professionals and VigiBase used by the World Health Organization (WHO), reporting by sponsors, and mandatory reporting by manufacturers involves data collection to the FDA Adverse Event Reporting Systems (FAERS) database which then reaches the FDA to make decisions on new warning labels or withdrawal/limited use of the product in the market.

Although pharmaceutical manufacturers, sponsors, and patient advocacy groups have realized the importance of good pharmacovigilance practices, pharmacovigilance activities and reporting continue to remain plagued by challenges. Underreporting, misreporting, missing and incomplete information, and inconsistences in safety data are considered common as they are entered into systems both voluntarily and in a non-standardized manner. Analysis of trends and patterns from a large volume of data is also difficult if not handled by advanced analytical techniques to draw meaningful conclusions. Thus, digital health technologies (DHT) are an important tool to improve pharmacovigilance by enabling collection and analysis of adverse events and safety data.

Digital health technologies (DHT) use computing platforms, connectivity, software, and sensors for healthcare and related uses. They include mobile medical apps (mHealth), artificial intelligence (AI), and machine learning (ML), wearable devices, telehealth and telemedicine, and personalized medicine.

There are two major ways in which DHTs are applicable in pharmacovigilance as shown in the Figure below:

Figure. Impact of DHT on Pharmacovigilance

Data collection

Wearable devices

DHTs such wearable devices including mobile phones, smart watches, fitness trackers, and mobile apps involve real-time collection and monitoring of data allowing adverse events to be detected, identified, and categorized as soon as they occur. This allows regulatory authorities and manufacturers to take immediate action and mitigate any potential risks.

Online platforms and social media

Online communities and social media websites serve as an important repository of safety concerns and information that are entered in by patients, advocacy groups, and caretakers. This information is important as it is entered directly in by patients and can help identify trends in safety data for certain drug classes and medical devices.

Electronic health records (EHRs)

EHRs are an important source of data for detection of adverse drug reactions and allow for cross-functional sharing of information with network of healthcare professionals enabling tracking and remediation of safety information. EHRs contain more detailed information such as timing of medication administration, symptom development, and detailed clinical history which may be of interest in understanding adverse events in a comprehensive manner.

Telemedicine

Telehealth platforms which involve remote visits and monitoring of patients without the need for in-person consultations are important for identification and communication of safety concerns by patients in a timely manner. This method allows physicians to understand adverse events and take appropriate adjustments such as stoppage of medication or dosage adjustments and can be integrated with EHRs.

Data analysis

Artificial intelligence (AI) and machine learning (ML)

These technologies serve to go through large amounts of data generated from wearable devices and process it to identify trends and patterns in safety data. AI allows for processing of pharmacovigilance reports and signal detection to extract information about potential adverse drug events. Data mining and prediction using AI and ML is also done on data obtained from social media platforms. ML techniques can be used to predict the probability of developing an adverse event based on patient history and characteristics and helps in the development of predictive models.

Data integration

Technologies such as AI and cloud computing are important in the field of pharmacovigilance which involves data extraction and analysis from a wide variety of sources into a single dataset to identify trends in safety information. These technologies are also important in ensuring data security and privacy.

Natural Language Processing (NLP)

This system helps extract structured safety and adverse event information from text-based documents such as EHRs, narrative reviews, and social media platforms.

Big data analytics

This is important for processing vast amounts of data and uses algorithms to extract meaningful insights regarding safety concerns linked to use of drugs or medical devices. It involves integration of diverse data form different sources to ascertain the causes of adverse events and is particularly useful when the data comes from unstructured sources such as (real-world evidence) RWE studies.

Therefore, application of DHT is a vital component of pharmacovigilance practices allowing more data to be handled in an accurate and timely manner which facilitating results in safety information to be identified rapidly and swift action by regulatory authorities to safeguard patient health.

References

Oct

Future Trends in Clinical Data Management

Data analytics, technology, and accessibility to the internet and healthcare has led to a paradigm shift in the way clinical trials have been conducted. Traditional clinical trials that have been used long since to generate data in support for approval of drugs, biological products, and medical devices, have historically used traditional methods for data collection, analysis, and storage or clinical data management (CDM) activities. Challenges to paper-based collection of data and data transcription are evident and limited by factors such as the experience and skill of professionals with data handling. Technological advancements have led to centralization of data management allowing data collection and storage from different sites to be performed in a secure and efficient manner. Electronic data capture (EDC) systems are widely used in present clinical trials that help streamline the process of collecting, storing, and securing data from multiple studies along with electronic case report forms (eCRF) and electronic clinical outcome assessment (eCOA), electronic patient-reported outcome (ePRO), electronic trial master file (eTMF), and e-consent.

These software systems are particularly useful for the decentralized clinical trial format that has gained popularity particularly after the COVID-19 pandemic. Nowadays, decentralized or hybrid trials in which some or all the trial activities are conducted remotely are widely used based on their several advantages such as improved patient recruitment and engagement, cost-effectiveness, real-time data collection, and more representative trial outcomes. Although advancements have been made in the design and conduct of trials, CDM activities are still catching up with these changes and need to evolve at the same pace to realize completely the benefits of these trial designs.

It is expected that the future if CDM will be driven by the following changes in trial design and conduct and data analysis as shown in the figure below:

Artificial intelligence (AI) and Machine learning (ML)

Processing vast amount of data from disparate sources to extract meaningful insights, trends, and patterns in relation to demographics, comorbidities, and adverse events requires ‘big’ data analytics and AI. CDM in the future would require employment of advanced data analytical techniques to deal with this vast amount of information. Natural language processing (NLP) algorithms are expected to be used to process large volumes of data and detect correlations in clinical data as well as extract insights from clinical notes written by physicians and healthcare professionals.

Decentralized and hybrid trials

CDM is likely to be shaped by trials that involve remote recruitment and monitoring of patients. Collection of health data from wearable devices such as mobile phones, smart watches, and telemedicine platforms requires a centralized system for collection and integration of data such as cloud-based systems.

Adaptive trial designs

These designs are unique as they involve mid-trial modifications or stoppage based ongoing information regarding the safety and efficacy of the product. Data collection, processing, and analysis should be flexible to allow documentation and feedback to the trial from these changes. Adaptive designs are commonly used in oncology and immunology trials which are complex and for ethical reasons.

Real-world evidence (RWE)

RWE studies are expected to be increasingly used in health-care decision making as they are representative of the real-world usage of a drug and safety concerns and provide monitoring of patients in real-time. Modification of data management services to accommodate RWE will include standardization of data from disparate sources and submission to regulatory authorities in conjunction with data from traditional clinical trials to make reliable decisions regarding product benefits.

Wearable technology

Increased accessibility and patient knowledge of health-tracking wearable devices involves data generation and sharing of a large volume of information that can be overwhelming to handle in the absence of suitable data analytics technology. Thus, management of data received from patients directly not only will need to be adequately handled and processed but also managed securely. Data privacy software, de-identification tools for data sets, and restricted accessibility to sensitive patient information will be the need of the hour in CDM practices.

Patient-centric activities

Clinical trials are moving from a central data management approach where investigators collect data and analyze it to a more patient-oriented approach where patients report their clinical outcomes and experiences allowing for a more complete understanding of product experience. It is important for CDM systems to be able to robust enough to securely access and interpret patient reports in an objective manner and develop validated PROs for use by patients.

Data privacy and security

The shift from traditional trials to use of remote monitoring, wearable sensors, telemedicine, and RWE studies that involve data sharing causes data security breach concerns which can compromise the reliability of trials and place patients at risk of losing sensitive information. Since the well-being and protection of human subjects is crucial for all trials, it is necessary for adequate data protection measures to be in place. Cybersecurity measures utilizing enhanced encryption technology, blockchain, and consent management systems will emerge important in CDM in the future.

References

Oct

The Impact of Real-World Evidence on Clinical Data Management

The increasing focus and acceptance of real-world data (RWD) in clinical decision making has led regulatory authorities and sponsors to understand its influence on data management that is an integral part of the clinical trial process. The United States Food and Drug Administration (FDA) defines RWD as data relating to patient health status and/or delivery of healthcare routinely collected from a variety of sources and real-world evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of RWD. There are various sources of RWD as shown in Figure 1

Figure 1. Sources of real-world data (RWD)

The FDA has also released several guidances that describe best practices for data standards, safety and efficacy determinations, and documentation standards for use of RWD and RWE in regulatory decision-making.

Although the benefits of including RWE in supporting regulatory decisions is important as it provides information on the safety and effectiveness of a product in real-life settings and diverse patient populations, allows for collection of data for a longer follow-up time than traditional clinical trials, and provides a comprehensive view on safety risks, and labelling recommendations, it is evident that the variety of data sources would create challenges in data management. Inconsistent data formats and vocabularies, differences in terminologies, methods, and algorithms to create datasets, and data privacy issues affect the reliability and accuracy of data and need to be addressed prior to the inclusion of RWE as a part of clinical data. The FDA recommends data transformation, conversions, and mappings of data to a standardized format, discussions with FDA when planning to use RWD, and application of Clinical Data Interchange Standards Consortium (CDISC) data standards such as Study Data Tabulation Model (SDTM) to RWD sources prior to regulatory submission.

As the primary difference in data generation and collection from controlled clinical trials and real-world settings relates to diversity and inconsistencies, it is important that CDM practices account for this difference and have processes in place to deal with it. The following are the ways in which RWE impacts CDM:

Data diversity

Collection of data from various sources with inconsistent formats requires a suitable data collection strategy or tool to cover all areas of data collection whether it be from registries or wearable technology.

Data volume

Since data is collected from diverse sources and from a significantly larger number of participants than traditional trials with varying data fields, it is reasonable to assume that the volume of data collected is considerable and is known as ‘big’ data. Dealing with this tremendous amount of data requires artificial intelligence (AI) and advanced analytics methods to retain data that is essential and extract suitable relevant information from it.

Data standardization and transformations

This is necessary to ensure the data are in consistent and reliable format in accordance with CDISC or other standards. This facilitates data sharing and ensure high-quality data especially when it is from disparate sources. Data cleaning and harmonization efforts are a significant

Data privacy and security

Collection of real-world data from wearable health technology and sensors improves patient convenience and allows for real-time monitoring. However, sharing sensitive personal information on apps and other web-based devices can cause a breach of privacy. Thus, it is critical to develop suitable security protection services and privacy regulations such as Health Insurance Portability and Accountability Act (HIPAA) in place when using electronic data exchanges in clinical trials and to remove identifiable information from datasets.

Data partners

RWE studies utilize information that is reported directly from patients using questionnaires, surveys, and patient-reported outcome (PRO) instruments which tend to be subjective and ambiguous thereby creating confusion and lack of trust in the collected data. Thereby it is important that Clinical Data Management services focus on the development of clear and simple PRO forms that are easy to understand and extract information from when entered in by patients and caretakers allowing for accurate data and improved patient engagement.

Regulatory modifications

Utilization of RWE to support regulatory decisions requires that RWD to be integrated into applications and regulatory submissions in the format that is required for a particular country. Therefore, CDM professionals need to be trained to understand the requirements and ensure that the data meets the format needed.

Type of trials

Most trials use RWD along with data from traditional clinical trials for drug approval processes requiring CDM personnel to be able to handle and utilize both types of data effectively.

Therefore, although RWE brings a plethora of information from the real-world, it is necessary to employ appropriate techniques for data handling, standardization, and presentation such that the information can be used effectively to support health-care decisions. CDM professionals and staff should be able to handle diverse and high-volume data by employing analytical tools for data extraction and understanding information for regulatory applications.

References

Oct

FDA’s Clinical Data Standard Requirements for Clinical Trials

Clinical trials are critical for the approval of new drugs and medical devices necessitating that data that is derived from them to make regulatory decisions is done so in a manner that generates accurate and reliable data. Thus, clinical data management is an integral component of all trials from patient recruitment and informed consent to statistical analysis as the approval of new products hinges upon this data. Clinical data management (CDM) includes all processes and activities that involve collection, validation, management, and storage of clinical trial data. To ensure the accuracy, integrity, and completeness of the collected data, there are certain data standards that must be adhered to throughout the trial process. This facilitates sound decision-making by regulatory authorities keeping not only efficacy and safety in mind but also patient well-being, and data security.

As per the United States Food and Drug Administration (FDA), study data standards describe a standard way to exchange clinical and nonclinical data. They provide a consistent general framework for organizing study data, including templates for data sets, standard names for variables, appropriate controlled terminology, and standard ways of analyzing data with common variables. The FDA website has a dedicated resource centre that describes tools and guidances for the submission of clinical data for drugs and biological products including real-world data which can be submitted electronically. It also includes specifications for certain products/conditions and specific studies such as those related to carcinogenicity.

FDA clinical data standards allow exchange of information between sponsors, investigators, and regulatory agencies and ensure accuracy, reliability, consistency, and interoperability. The FDA has adopted Clinical Data Interchange Standards Consortium (CDISC) standards. CDISC is a multidisciplinary, non-profit organization that has developed standards to support acquisition, exchange, submission, and archival of clinical data and metadata to track deletions or modifications to entered data. CDISC has developed global standards for clinical studies and data sharing and includes data collection templates, data formatting tools, and dataset structures that allows for standardized methods for collection, managing, and sharing of clinical data. These templates and standardized data forms ensure reliability of data especially when clinical trials are conducted globally, and several trial sites and coordinators are involved.

The CDM process is composed of several steps such as data form design, data entry and validation, data cleaning, database management, quality assurance, data reconciliation, database lock and archival and storage. In multi-site trials and to allow for exchange of data with regulatory authorities, data transfer, privacy, and security are important aspects of the CDM process.

Figure 1 shows the clinical standards applied by the FDA for different steps of the data management process as per CDISC.

Figure 1. CDISC standards for clinical data management

Clinical Data Acquisition Standards Harmonization (CDASH)

Is CDISC’s standard for data collection and data capture. CDASH provides a standard way to collect data consistently across studies and sponsors that allows for traceability of data and transparency to regulators and integrates with SDTM and ADaM creating consistency throughout the trial lifecycle. It can be used to create case report forms (CRFs) and provides templates for CRFs with standardized data collection fields such as interventions, demographics, medical history, adverse events, and laboratory tests. CDASH is compatible with a variety of electronic data capture (EDC) systems and utilizes standardized terminology and coding to describe medical issues thereby removing ambiguity in the collection process. The goal of CDASH is to ensure collection of high-quality and standardized data.

Study Data Tabulation Model (SDTM)

Provides a standard for organizing and formatting data to streamline processes in collection, management, analysis, and reporting. This CDISC standard organizes data into various domains such as demographics, adverse events, laboratory tests, concomitant medications, vital signs, etc. for submission to regulatory agencies and is used widely by global regulatory agencies and academic centres. It is necessary for raw data to be transformed to and validated to SDTM-compliant domains using mapping specifications to minimize inconsistencies and errors. SDTM makes data sharing and analysis easier as data is standardized.

Analysis Data Model (ADaM)

Is a set of dataset and metadata standards and guidelines developed by CDISC that describes the preparation and organization of analysis datasets for clinical trials. It allows for efficient generation, replication, and review of clinical trial statistical analyses and traceability. The main purpose of ADaM is to provide standardized structures for datasets that allows for analysis and speeds up submission and regulatory processes. The datasets include domains and variables that should be included in the datasets and uses CDISC standardized terminology and describes guidelines for the use of statistical analysis software like SAS.

Controlled terminology

It is the set of codelists and valid values used with data items within CDISC-defined datasets and provides guidance on submission of data items in electronic datasets. It provides a standardized way to describe and document data allowing for uniformity across different data collection platforms. The controlled terminology is organized into domains which contains items and terms with specific definitions and synonymous terms along with data type and format on how the data should be reported. The overall aim of controlled terminology is to ‘speak a common language’ and allow for crosstalk between studies and is necessary for regulatory compliance.

Electronic Common Technical Document (eCTD)

Facilitates submission of nonclinical, clinical, and manufacturing information to regulatory agencies using a structured format. It helps streamline submissions allowing for easier review and processing by regulatory agencies and this format is mandatory for submissions to the FDA. Data that is organized as per SDTM and ADaM standards can be included in eCTD submissions.

Adherence to clinical data standards is important for regulatory submissions and helps ensure accuracy, consistency, interoperability, and traceability of data. This is particularly important today as global clinical trials are gaining popularity and most data is entered electronically for data sharing that is amenable to standardization. CDISC standards can be integrated with each other and ensure high data quality throughout clinical trials and are used by the FDA.

References

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.